Journals / Journal of Neurological Sciences (Turkish) / 2016 / Cilt: 33 - Sayı: 1

Epizodik ve Kronik Migrende Orexin-A Düzeyleri: Hipotalamik Tutulumun Etkisi Mi?

Orexin-A Levels in Episodic and Chronic Migraine: Implications For Hypothalamic Involvement?

Pages
56–63
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further larger studies may shed more light on the role of the orexinergic system and the hypothalamus in migraine and the chronification of it

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the study was to demonstrate whether blood Orexin A levels (OX-AL), which are a marker of hypothalamic activity, are altered in patients with migraine and whether they differ ictally and interictally and with the chronification of migraine.
📊
Key Findings & Data:Materials and Methods: A total of 113 patients participated in this study.
💡
Conclusion & Impact:Further larger studies may shed more light on the role of the orexinergic system and the hypothalamus in migraine and the chronification of it
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the study was to demonstrate whether blood Orexin A levels (OX-AL), which are a marker of hypothalamic activity, are altered in patients with migraine and whether they differ ictally and interictally and with the chronification of migraine. Materials and Methods: A total of 113 patients participated in this study. Orexin A blood samples were taken during a headache-free interval. In 17 patients with episodic migraine a second blood sample for Orexin A was taken during an attack of migraine. Results: OX-AL were lower in episodic migrane compared to controls but did not differ during an attack and the interictal period. Conclusion: Our findings of low OX-AL in episodic migrane both ictally and interictally, similar levels of OX-AL in chronic migraine and tension-type headache compared to controls may suggest that OX-AL is probably not released in response to acute pain but its basal levels may modulate the susceptibility to pain. Basal OX-AL are low in patients with episodic migrane which could reflect a suppression of the orexinergic system due to hypothalamic dysfunction but increase with chronification possibly in response to lower Orexin-A receptor density secondary to neurodegeneration. Further larger studies may shed more light on the role of the orexinergic system and the hypothalamus in migraine and the chronification of it

Özet

Amaç: Bu çalışmanın amacı, hipotalamik aktivitenin bir belirteci olan kan Oreksin-A düzeylerinin migren hastalarında değişiklik gösterip göstermediğini ve migrenin kronikleşmesi ile iktal ve interiktal periyotta farklılık gösterip göstermediğini ortaya koymaktır. Materyal-Metot: Bu çalışmaya 113 hasta dahil edildi. Oreksin-A kan örnekleri baş ağrısının olmadığı dönemde alındı. Epizodik migreni olan 17 hastada migren atağı esnasında ikinci kan örneği alındı. Sonuçlar: Oreksin A düzeyleri, epizodik migren grubunda kontroller ile karşılaştırıldığında daha düşüktü ama atak ve interiktal periyotta değişiklik göstermedi. Sonuç: Epizodik migrende iktal ve interiktal Oreksin-A düzeylerinin düşük olması ve kontrol grubu ile karşılaştırıldığında kronik migren ve gerilim tipi başağrısında benzer düzey OreksinA düzeyleri, Oreksin-A'nın muhtemelen akut ağrıya cevap olarak salınmadığı ve bazal düzeylerinin ağrıya duyarlılığı modüle edebileceğini önermektedir. Epizodik migren hastalarında bazal Oreksin-A düzeylerinin düşük olması, hipotalamik disfonksiyona bağlı oreksinerjik sistemin baskılanmasını yansıtabilir, ama kronikleşme ile birlikte artması muhtemelen nörodejenerasyona sekonder düşük oreksin reseptör yoğunluğuna ikincil olabilir.Daha büyük çalışmalar migren ve kronikleşmesinde oreksinerjik sistem ve hipotalamusun rolünü daha fazla aydınlatabilir

🔖

Cite This Article

ÖZDEM, S., DORA, B., GÖKSU, E. Ö., UZUN, N., ÜNAL, A. (2022). Epizodik ve Kronik Migrende Orexin-A Düzeyleri: Hipotalamik Tutulumun Etkisi Mi?. Journal of Neurological Sciences (Turkish), Cilt: 33 - Sayı: 1, 56–63. https://ajindex.com/articles/564849

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bartsch T, Levy MJ, Knight YE, and Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004;109:367-378.
  2. Bezov D, Ashina S, Jensen R, et al. Pain perception studies in tension-type headache. Headache 2011; 51:262-271.
  3. Bingham S, Davey PT, Babbs AJ, et al. Orexin- A, a hypothalamic peptide with analgesic properties. Pain 2001; 92: 81-90.
  4. Cevoli S, Pizza F, Grimaldi D, et al. Cerebrospinal fluid hypocretin-1 levels during the active period of cluster headache. Cephalalgia 2011; 31:973-976.
  5. Cheng JK, Chou RC, Hwang LL, et al. Antiallodynic effects of intrathecal orexins in rat model of postoperative pain. J Pharmacol Exp Ther 2003; 307:1065-1071.
  6. Dahmen N, Kasten M, Wieczorek S, et al. Increased frequency of migraine in narcoleptic patients: A confirmatory study. Cephalalgia 2003; 23:14-19.
  7. Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. Headache 2007; 47:1418- 1426. Ferguson AV, Samson WK. The orexin/hypocretin system: A critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol 2003; 24:141-150.
  8. Giraud P, Chauvet S. Migraine and obesity, is there a link? Rev Neurol (Paris) 2013; 169:413-418.
  9. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005; 315:1380-1385.
  10. Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006; 24:2825-2833.
  11. Holland P, Goadsby PJ. The hypothalamic Orexinergic System: pain and Primary Headaches. Headache 2007; 47: 951-62.
  12. Hoskin KL, Bulmer DC, Lasalandra M, et al. Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. J Anat 2001; 198(Pt 1):29-35.
  13. Kajiyama S, Kawmoto M, Shiraishi S, et al. Spinal orexin 1 receptors mediate anti- hyperalgesic effects of intathecally- administered orexins in diabetic neuropathic pain model rats. Brain Res 2005; 1044: 76-86.
  14. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine. Neuroscience 2001; 106:793-800.
  15. Millan MJ, Przewlocki R, Millan MH, et al. Evidence for a role of the ventro-medial posterior hypothalamus in nociceptive processes in the rat. Pharmacol Biochem Behav 1983; 18:901-907. Olesen e